Stockscreener 앱 받기
15.67
3.27%
-0.53
전일 마감가:
$16.20
열려 있는:
$16.11
하루 거래량:
1.21M
Relative Volume:
0.80
시가총액:
$1.32B
수익:
-
순이익/손실:
$-44.17M
주가수익비율:
-29.79
EPS:
-0.526
순현금흐름:
$-35.14M
1주 성능:
+2.89%
1개월 성능:
+40.41%
6개월 성능:
+130.78%
1년 성능:
+268.71%
1일 변동 폭
$15.27
$16.20
1주일 범위
$14.93
$16.47
52주 변동 폭
$3.96
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
명칭
Corvus Pharmaceuticals Inc
전화
(650) 900-4520
주소
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
15.67 | 1.32B | 0 | -44.17M | -35.14M | -0.526 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Goldman | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-01-02 | 개시 | H.C. Wainwright | Buy |
| 2023-08-18 | 개시 | Oppenheimer | Outperform |
| 2021-12-01 | 재개 | Jefferies | Buy |
| 2021-05-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-02-10 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-09-12 | 개시 | Mizuho | Buy |
| 2019-05-29 | 개시 | ROTH Capital | Buy |
| 2017-08-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 개시 | Credit Suisse | Outperform |
| 2016-04-18 | 개시 | Guggenheim | Buy |
모두보기
Corvus Pharmaceuticals Inc 주식(CRVS)의 최신 뉴스
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
Corvus Pharmaceuticals (CRVS) Proxy filing Summary - Quartr
CRVS News | CORVUS PHARMACEUTICALS INC (NASDAQ:CRVS) - ChartMill
Corvus Pharmaceuticals (CRVS) Q4 2024 earnings summary - Quartr
Corvus Pharmaceuticals (CRVS) Stock Analysis Report | Financials & Insights - Benzinga España
Corvus Pharmaceuticals (CRVS) Gains 1.42% as Biotech Momentum Lifts Speculative NamesDaily Profile - dars.gov.et
Is Corvus Pharmaceuticals (CRVS) Still Undervalued After Its Share Price Jump? - Sahm
Corvus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:CRVS) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (BX:C17) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (SWB:C17) - TradingView
Corvus Pharmaceuticals, Inc. Actuals & Estimates (DUS:C17) - TradingView
CRVS Forecast — Price Target — Prediction for 2027 - TradingView
Corvus Pharmaceuticals (CRVS) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Price to book forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Price to sales forward of Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS - TradingView
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? - Yahoo Finance
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? - The Motley Fool
Corvus Pharmaceuticals Inc (CRVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Institutional Confidence - TradingKey
Insider Buys Additional US$250k In Corvus Pharmaceuticals Stock - simplywall.st
Corvus Pharmaceuticals Inc (CRVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Corvus CEO thinks his next blockbuster is an ITK inhibitor - Pharma Voice
Corvus Pharmaceuticals (CRVS) director buys 21,700 shares and receives 15,000-share option - Stock Titan
[Form 4] Corvus Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Corvus Pharmaceuticals (CRVS) director receives grant of 15,000 stock options - Stock Titan
Director at Corvus (CRVS) receives grant of 15,000 stock options - Stock Titan
Corvus (CRVS) director awarded options for 15,000 shares at $11.60 - Stock Titan
Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest - Yahoo Finance
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? - Insider Monkey
Corvus Stockholders Approve Directors and Governance Proposals - TipRanks
Corvus Pharmaceuticals (CRVS) posts 2026 annual shareholder meeting voting outcomes - Stock Titan
Corvus Hikes on Position in Angel - Baystreet.ca
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China - The Manila Times
$13.5M bet on soquelitinib: China eczema and asthma trials move ahead - Stock Titan
Corvus Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
CRVS: Soquelitinib progresses in pivotal trials for PTCL and AD, targeting broad immunology markets - TradingView
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Corvus drops after early-stage trial data for eczema therapy - MSN
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness - simplywall.st
CRVSCorvus Pharmaceuticals Inc Latest SEC Filings - Finviz
Corvus Pharmaceuticals to present at major healthcare conferences in June 2026 - Pluang
Corvus (CRVS) CEO adds 6,932 shares via Miller-Horning family trust - Stock Titan
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
Corvus Pharmaceuticals Inc (CRVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):